NCT05171816 2026-03-11Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)AstraZenecaPhase 3 Active not recruiting110 enrolled 12 charts
NCT02987543 2023-10-06Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)AstraZenecaPhase 3 Completed387 enrolled 16 charts 2 FDA